Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Renal Cell × Pluvicto × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18 Kidney Neoplasms 2 Urogenital Neoplasms 1 Thrombocytopenia 1 Renal Insufficiency 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Liver Neoplasms 1 Genital Neoplasms, Male 1 Cytopenia 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Anemia 1

Interventions

Sunitinib 52 Nivolumab 45 Sorafenib 35 Bevacizumab 31 Axitinib 31 pembrolizumab 29 cabozantinib 28 Everolimus 25 pazopanib 23 aldesleukin 23 Ipilimumab 21 Interleukin-2 17 Magnetic Resonance Spectroscopy 15 Interferon-alpha 15 Gemcitabine 15 lenvatinib 13 Specimen Handling 13 Radiosurgery 12 Interferon alpha-2 12 Cyclophosphamide 12 fludarabine phosphate 11 Erlotinib Hydrochloride 8 temsirolimus 7 atezolizumab 7 Introns 7 Capecitabine 7 durvalumab 6 avelumab 6 Radiotherapy 6 Peripheral Blood Stem Cell Transplantation 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06964958 2026-02-24

LASER

Dana-Farber Cancer Institute

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡